GlobeNewswire Inc.··NaTiziana Completes MS Trial Enrollment, Eyes Late 2026 Data Read
Tiziana Life Sciences completes enrollment of 48-patient Phase 2 MS trial, with topline data expected late Q3 2026 at ACTRIMS/ECTRIMS conference.
TLSAPhase 2a clinical trialneuroinflammation